Nat. Biotechnol. 36, 287 (2018); published online 5 April 2018; corrected after print 15 May 2018
In the version of this article initially published, paragraphs 2 and 3, it was stated that Oxford Nanopore Technologies (ONT) “announced an early access program to make available the MinION—a device containing the Mycobacterium smegmatis porin A (MspA) nanopore. The following year, ONT launched its first commercial product containing 'flow cells' featuring >500 MspA pores in a lipid monolayer.” As ONT has never disclosed what pores the early-access MinION used, the references to MspA have been removed. In addition, since the company has never used lipids and its membrane material is a trade secret, the second sentence has also been corrected. In paragraph 4, sentence 1 “Today, ONT's MinION can process up to 450 bases of DNA per second. Read-lengths in excess of 800,000 bases (ultra-long reads) are being reported in different laboratories...” had several inaccuracies. The MinION processes 450 bases of DNA per second “per channel.” Rather than read-lengths in excess of “800,000 bases,” reports are of read-lengths in excess of “1.3 Mb.” In the paragraph preceding the penultimate paragraph, the sentence “ONT would do well to take a leaf from Pacific Biosciences, which has encouraged open-source software development for its platform” overlooked two contributions by ONT, and has been revised. The errors have been corrected in the HTML and PDF versions of the article.
Author information
Consortia
Additional information
The online version of the original article can be found at https://doi.org/10.1038/nbt.4125
Rights and permissions
About this article
Cite this article
Anonymous. Erratum: The long view on sequencing. Nat Biotechnol 36, 772 (2018). https://doi.org/10.1038/nbt0818-772b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0818-772b
This article is cited by
-
Whole Genome Sequence of Xylella fastidiosa ATCC 35879T and Detection of Genome Rearrangements Within Subsp. fastidiosa
Current Microbiology (2020)
-
Viral contamination in biologic manufacture and implications for emerging therapies
Nature Biotechnology (2020)